The Mechanism of Leukoregulin Enhancement of Target Cell Susceptibility to NK Cell Mediated Cytotoxicity in Humans

  • Janet H. Ransom
  • Charles H. Evans
  • Richard P. McCabe
  • M. G. HannaJr.
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 187)


Leukoregulin is an anticancer immunologic hormone or lymphokine whose actions include the inhibition of tumor cell growth and lysis of tumor cells either directly or indirectly by stimulating target cell sensitivity to lysis mediated by natural killer (NK) cells (1, 2, 3). Only a few cell types are directly lysed by leukoregulin and lysis requires very large leukoregulin concentrations. Leukoregulin enhancement of target sensitivity to NK cell cytolysis, however, occurs in the presence of small concentrations of leukoregulin for carcinoma, sarcoma, and leukemia tumor cells (4). Therefore, the primary in vivo means of tumor destruction may be through the combined action of leukoregulin and NK cells.


Natural Killer Natural Killer Cell K562 Cell Transferrin Receptor Natural Killer Cytotoxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Ransom, J.H., L.S. Cleveland, R.P. McCabe, and M.G. Hanna, Jr. Human gastrointestinal carcinoma cells are highly susceptible to the growth inhibitory effects of the immunologic hormone leukoregulin. Proc. Amer. Assoc. Cancer Res. 25:236 (1984).Google Scholar
  2. 2.
    Cleveland, L.S., J.H. Ransom, and C.H. Evans. Leukoregulin: A new anticancer lymphokine distinct from lymphotoxin and interferon. Fed. Proc. 43:1931 (1984).Google Scholar
  3. 3.
    Evans, C.H., J.H. Ransom, and J.A. Heinbaugh. Leukoregulin: A molecular mediator of natural killer cell cytotoxicity. Proc. Amer. Assoc. Cancer Res. 25:268 (1984).Google Scholar
  4. 4.
    Ransom, J.H., J.A. Heinbaugh, and C.H. Evans. Leukoregulin: identification of an anticancer immunologic hormone distinct from lymphotoxin and interferon (submitted for publication, 1984).Google Scholar
  5. 5.
    Granger, G.A., and W.P. Kolb. Lymphocyte in vitro cytotoxicity: mechanisms of immune and non-immune small lymphocyte mediated target L cell destruction. J. Immunol. 101:111 (1968).PubMedGoogle Scholar
  6. 6.
    Ransom, J.H., and C.H. Evans. Molecular characterization of Syrian hamster lymphotoxin’s anticarcinogenic and growth inhibitory activities. Cancer Res. 43:5222 (1983).PubMedGoogle Scholar
  7. 7.
    Grimm, E., and B. Bonavida. Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency. J. Immunol. 123:2861 (1979).PubMedGoogle Scholar
  8. 8.
    Baines, M.G., F.L. LaFleur, and B.E. Holbein. Involvement of the transferrin and transferrin receptors in human natural killer effector: target interaction. Immunol. Letters 7:51 (1983).CrossRefGoogle Scholar
  9. 9.
    Wright, S.C., M.L. Weitzen, R. Kahle, G.A. Granger, and B. Bonavida. Studies on the mechanism of natural killer cytotoxicity. II. Coculture of human PBL with NK-sensitive or resistant cell lines stimulates release of natural killer cytotoxic factors (NKCF) selectively cytotoxic to NK-sensitive target cells. J. Immunol. 130:2479 (1983).PubMedGoogle Scholar
  10. 10.
    Bonavida, B., and S.C. Wright. Soluble cytotoxic factors and the mechanism of NK cell mediated cytotoxicity. Adv. Exp. Med. Biol. 146:379 (1982).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1985

Authors and Affiliations

  • Janet H. Ransom
    • 1
  • Charles H. Evans
    • 2
  • Richard P. McCabe
    • 1
  • M. G. HannaJr.
    • 1
  1. 1.Litton Institute of Applied BiotechnologyRockvilleUSA
  2. 2.Div. of Cancer EtiologyNational Cancer Inst.BethesdaUSA

Personalised recommendations